Karina Tschon works as an Attorney at Law at Walder Wyss. She advises clients on matters of commercial and corporate law.

Born in 1990, Karina Tschon studied at the University of Basel (BLaw 2014, MLaw 2016). Prior to joining Walder Wyss as an Attorney at Law, she worked as a trainee lawyer at the Civil District Court Basel-Landschaft East, the Criminal Court of Basel-Stadt, in a law firm in Basel and in the legal department of a pharmaceutical company in Basel. Karina Tschon was admitted to the bar in 2019 in the canton of Basel-Stadt.

Karina Tschon's professional languages are German and English.

Significant Accomplishments

SixPeaks Bio AG debuts with USD 110 million in Funding

Promotions at Walder Wyss

Nouscom Raises €67.5m ($72m) in Oversubscribed Series C Financing Round

LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections

Pierre Fabre Laboratories acquires Vertical Bio AG

Alentis Therapeutics Closes USD 105m Series C Funding

Investorengruppe erwirbt iPet.ch GmbH

BC Platforms Announces USD 20 Million Growth Financing led by Jolt Capital

Versant Ventures launches Vector BioPharma with USD 30m Series A

BioVersys announces successful first closing of CHF 24.2 million Series C financing to develop clinical pipeline of novel AMR therapies

ImmunOs Therapeutics Raises USD 74 Million Series B Financing Round

Astorg acquires CordenPharma from ICIG

Engimmune Therapeutics raises CHF 15.5m in Seed Financing

Versant Ventures launches Cimeio Therapeutics with USD 50m Series A

kooky sichert sich Finanzierung über EUR 6 Millionen

Memo Therapeutics Closes Series B Financing at CHF 37m Following Oversubscribed CHF 23m Extension

Alloy Therapeutics acquires deepCDR Biologics

GlycoEra CHF 45m Series A Financing

Perconex Holding GmbH kauft Flex Suisse AG

Polyphor and EnBiotix sign merger agreement and agreement on sale of Murapavadin

Alentis Therapeutics erhält USD 67 Mio. im Rahmen einer Serie-B-Finanzierung

proLogistik Holding GmbH erwirbt XELOG AG

Calibre Scientific, Inc. acquires HUBERLAB.AG

Boehringer Ingelheim kauft NBE-Therapeutics für EUR 1,18 Milliarden

Noema Pharma Serie A-Finanzierungsrunde über CHF 54 Mio.

Synendos Therapeutics CHF 20m Series A Financing

VectivBio USD 110m Crossover Financing

Monte Rosa Therapeutics Serie B-Finanzierungsrunde über USD 96 Mio.

BioVersys Serie B-Finanzierungsrunde über CHF 19 Mio.

Versant Ventures lanciert Matterhorn Biosciences

Versant Ventures bringt Bright Peak Therapeutics auf den Markt

Walder Wyss berät BC Platforms im Hinblick auf die Series C Finanzierung über USD 15 Millionen sowie eine Partnerschaft mit IQVIA zum Ausbau der Datenanalytik im Bereich Genomik